Aytu BioPharma amends warrants, cuts liability
Aytu BioPharma, Inc. entered into amended and restated warrant agreements with institutional investors on March 31, 2026, replacing June 2023 and June 2025 prefunded and Tranche A warrants with revised beneficial ownership blockers.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Aytu BioPharma, Inc. entered into amended and restated warrant agreements with institutional investors on March 31, 2026, replacing June 2023 and June 2025 prefunded and Tranche A warrants with revised beneficial ownership blockers. The new language clarifies that stockholders cannot vote to amend or change these blockers.
Previously, ambiguity around the blockers led the company, under ASC Topic 480 and ASC Topic 815, to classify the warrants as liabilities, recording a warrant liability of $18.1 million for the quarter ended September 30, 2025 and $25.2 million for the quarter ended December 31, 2025. Following the amendments, the company expects its warrant liability to decrease and its equity value to increase by the same amount.
Insights
Aytu cleans up warrant terms to restore equity accounting.
Aytu BioPharma discovered that blocker language in its 2023 and 2025 warrants required them to be treated as liabilities under ASC 480 and ASC 815, creating warrant liabilities of $18.1 million and $25.2 million in late 2025.
By canceling the old warrants and issuing amended versions that clearly prevent stockholders from changing the ownership blockers, the company expects future equity classification. This should reduce recorded liabilities and increase reported equity by the same amount, improving the balance sheet presentation without changing underlying cash flows.
8-K Event Classification
5 items: 1.01, 2.02, 3.02, 3.03, 9.01
5 items
Item 1.01
Entry into a Material Definitive Agreement
Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 3.02
Unregistered Sales of Equity Securities
Securities
The company sold equity securities in a private placement or other unregistered transaction.
Item 3.03
Material Modification to Rights of Security Holders
Securities
A change was made that materially affects the rights of existing shareholders (e.g., dividend rights, voting rights).
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Warrant liability: $18.1 million
Warrant liability: $25.2 million
Amended instruments: 3 warrants
3 metrics
Warrant liability
$18.1 million
Recorded for quarter ended September 30, 2025
Warrant liability
$25.2 million
Recorded for quarter ended December 31, 2025
Amended instruments
3 warrants
Amended 2023 Prefunded, 2023 Tranche A, 2025 Prefunded on March 31, 2026
Key Terms
beneficial ownership blockers, Nasdaq Capital Market LLC ownership blockers, ASC Topic 480, ASC Topic 815, +2 more
6 terms
beneficial ownership blockers financial
"stockholder approval language relating to beneficial ownership blockers and Nasdaq Capital Market LLC ownership blockers"
Nasdaq Capital Market LLC ownership blockers financial
"stockholder approval language relating to beneficial ownership blockers and Nasdaq Capital Market LLC ownership blockers"
ASC Topic 480 financial
"authoritative guidance in Financial Accounting Standards Board Accounting Standards Codification (“ASC”) Topic 480, Distinguishing Liabilities from Equity"
ASC Topic 815 financial
"ASC Topic 480, Distinguishing Liabilities from Equity and ASC Topic 815, Derivatives and Hedging"
Section 3(a)(9) regulatory
"in reliance upon Section 3(a)(9) of the Securities Act, as an exchange of securities"
Section 3(a)(9) is a provision of U.S. securities law that exempts certain exchanges of an issuer’s own securities with its existing holders from the usual public registration rules, typically when the swap doesn’t involve a public offering or outside buyers. For investors, it matters because such exchanges can change who holds what, affect dilution and liquidity, and may occur with less public disclosure than a registered sale — think of it like swapping old coupons for new ones behind the scenes rather than selling them in a public marketplace.
Rule 506 regulatory
"Section 4(a)(2) of the Securities Act and Rule 506 promulgated thereunder"
A Securities and Exchange Commission rule that lets companies sell securities without registering them with the SEC when they meet certain conditions, commonly used for private placements. It allows issuers to raise unlimited capital from accredited investors and, in some versions, a small number of knowledgeable non‑accredited investors; one version also permits public advertising if the seller takes steps to verify investor credentials. For investors, it signals a private offering with lighter disclosure and different protections than a public stock sale, similar to buying into a private club rather than a publicly traded marketplace.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Aytu BioPharma (AYTU) change in its warrant agreements?
Aytu BioPharma amended and restated its June 2023 and June 2025 prefunded and Tranche A warrants. The revisions clarify that stockholders cannot vote to amend the ownership blockers, supporting equity classification for these warrants instead of liability treatment under accounting rules.
Why were Aytu BioPharma’s AYTU warrants previously classified as liabilities?
While preparing its September 30 and December 31, 2025 quarterly reports, Aytu concluded that ambiguous blocker language required liability classification. Under ASC Topic 480 and ASC Topic 815, this led to recording warrant liabilities of $18.1 million and $25.2 million for those respective quarters.
How will the AYTU warrant amendments affect Aytu BioPharma’s balance sheet?
Aytu BioPharma expects that, after amending the warrants, its recorded warrant liability will decrease and equity will increase by the same amount. This change is accounting-driven, improving reported equity without altering the company’s cash position or operating performance.
Which specific Aytu BioPharma warrants were amended in this 8-K?
The company entered into an Amended 2023 Prefunded Warrant, an Amended 2023 Tranche A Warrant, and an Amended 2025 Prefunded Warrant. These new instruments replace the previously issued warrants to fix ownership blocker language affecting their accounting treatment.
Under what exemptions were Aytu BioPharma’s amended AYTU warrants issued?
To the extent the amendments are deemed new securities, Aytu issued the amended warrants without registration under the Securities Act. The company relied on Section 3(a)(9) for exchanges and Section 4(a)(2) and Rule 506 for private, non-public offerings to institutional investors.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
|
|
|
|
||
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
(Address of principal executive offices, including zip code)
(720 ) 437-6580
(Registrant’s telephone number, including area code)
Not applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of Each Class
|
Trading Symbol(s)
|
Name of Each Exchange on Which Registered
|
||
|
|
|
The
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 1.01 Entry into a Definitive Material Agreement.
As previously disclosed, Aytu BioPharma, Inc. (the “Company”) completed public equity offerings in June 2023 and June 2025 whereby the Company issued certain warrants and prefunded warrants (collectively, the “Warrants”) to certain institutional investors (the “Investors”).
In connection with the preparation of its Quarterly Reports on Form 10-Q for the quarters ended September 30, 2025, and December 31, 2025, the Company with consultation with its advisors, determined that the inclusion of certain stockholder approval language relating to beneficial ownership blockers and Nasdaq Capital Market LLC ownership blockers (the “Blockers”) created ambiguity from an accounting perspective that would require the Company to classify the Warrants as liabilities rather than equity in its financial statements based on applicable authoritative guidance in Financial Accounting Standards Board Accounting Standards Codification (“ASC”) Topic 480, Distinguishing Liabilities from Equity and ASC Topic 815, Derivatives and Hedging. As a result of the classification of the Warrants as liabilities, the Company was required to record a liability of $18.1 million and $25.2 million in the quarters ended September 30, 2025, and December 31, 2025, respectively.
As a result of the determination that the Warrants would be classified as liabilities as long as the Warrants remained outstanding despite management’s belief that the Warrants were intended to be classified as equity, the Company and the Investors agreed to make changes to the Blockers to address the unintended accounting treatment in order to provide for equity classification going forward and agreed to amend the Warrants.
On March 31, 2026, the Company and the Investors, as applicable, entered into (i) an Amended and Restated June 2023 Prefunded Warrant (“Amended 2023 Prefunded Warrant”), (ii) an Amended and Restated June 2023 Tranche A Warrant (“Amended 2023 Tranche A Warrant”) and (iii) an Amended and Restated June 2025 Prefunded Warrant (“Amended 2025 Prefunded Warrant”), pursuant to which the Company canceled the previously issued Warrants and issued to the Investors, as applicable, an Amended 2023 Prefunded Warrant, an Amended 2023 Tranche A Warrant and an Amended 2025 Prefunded Warrant, with revised Blockers.
Under the Blockers that were included in the Warrants prior to their amendment on March 31, 2026, it was unclear whether the Company’s stockholders could vote to amend or change the Blockers. The Warrants were amended to make clear that a vote of the Company’s stockholders could not amend or change the Blockers.
The Company expects that following the amendments of the Warrants that its warrant liability on its financial statements will be reduced and its equity value will increase by that same amount.
A copy of the Amended 2023 Prefunded Warrant is attached hereto as Exhibit 4.1, a copy of the Amended 2023 Tranche A Warrant is attached hereto as Exhibit 4.2 and a copy of the Amended 2025 Prefunded Warrant is attached hereto as Exhibit 4.3. The foregoing description of the Warrants, as amended, is qualified by reference to the full text of the Warrants, as amended, which are attached hereto.
Item 2.02 Results of Operations and Financial Condition.
See the disclosures in Item 1.01 of this report, which are incorporated herein by reference.
Item 3.02 Unregistered Sales of Equity Securities.
See the disclosures in Item 1.01 of this report, which are incorporated herein by reference.
To the extent that the amendment of the Warrants may be deemed to be the issuance of new securities, the issuance of the Warrants, as amended, was not registered under the Securities Act of 1933, as amended (“Securities Act”), in reliance upon Section 3(a)(9) of the Securities Act, as an exchange of securities, and Section 4(a)(2) of the Securities Act and Rule 506 promulgated thereunder, as a transaction by an issuer not involving a public offering.
Item 3.03 Material Modification to Rights of Security Holders.
See the disclosures in Item 1.01 of this report, which are incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit Number
|
Exhibit Description
|
|
|
4.1
|
Form of Amended 2023 Prefunded Warrant
|
|
| 4.2 | Form of Amended 2023 Tranche A Warrant | |
| 4.3 | Form of Amended 2025 Prefunded Warrant | |
|
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
AYTU BIOPHARMA, INC.
|
||
|
Date: April 2, 2026
|
By:
|
/s/ Ryan J. Selhorn
|
|
Ryan J. Selhorn
|
||
|
Chief Financial Officer
|
||
Filing Exhibits & Attachments
7 documentsOther Documents
- EX-4.1 EXHIBIT 4.1 97.7 KB
- EX-4.2 EXHIBIT 4.2 117.7 KB
- EX-4.3 EXHIBIT 4.3 100.3 KB
- EX-101 XBRL TAXONOMY EXTENSION SCHEMA 3.5 KB
- EX-101 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE 11.5 KB
- EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 15.5 KB
- EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 11.7 KB